Opus Genetics, Inc. Gain (Loss) on Extinguishment of Debt
Opus Genetics, Inc. (IRD) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2022-03-24
- Opus Genetics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Opus Genetics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2021-09-30 was $0.00.
- Opus Genetics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Opus Genetics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2021-03-31 was $0.00.
- Opus Genetics, Inc. gain (loss) on extinguishment of debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Opus Genetics, Inc. gain (loss) on extinguishment of debt for fiscal 2020 was $3.67M.
- Opus Genetics, Inc. gain (loss) on extinguishment of debt for fiscal 2019 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $0.00 derived: sum of 2 quarters · filed 2022-03-24 | $0.00 derived: sum of 3 quarters · filed 2022-03-24 | $0.00 10-K · filed 2022-03-24 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | $2.41M derived: sum of 4 quarters · filed 2022-03-24 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $2.41M derived: sum of 3 quarters · filed 2022-03-24 | $2.41M derived: sum of 4 quarters · filed 2022-03-24 |
| 2021-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2022-03-24 | $2.41M derived: sum of 2 quarters · filed 2022-03-24 | $2.41M derived: sum of 3 quarters · filed 2022-03-24 | $3.67M derived: sum of 4 quarters · filed 2022-03-24 |
| 2020-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $2.41M derived: sum of 2 quarters · filed 2022-03-24 | $3.67M derived: sum of 3 quarters · filed 2022-03-24 | $3.67M 10-K · filed 2022-03-24 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 | $1.26M derived: sum of 2 quarters · filed 2021-11-12 | $1.26M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $1.26M 10-Q · filed 2021-08-12 | $1.26M 10-Q · filed 2021-08-12 | ||
| 2019-12-31 | $0.00 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |